Two startups based on Purdue research receive $100,000 in funding | SPEAK MODalities
Summary
Jewell Laboratories, based on research by Purdue professor of chemistry David H. Thompson, has developed a family of compounds that could benefit people affected by Niemann-Pick Type C disease. “We will focus on delivering pre-clinical results of our proprietary compounds as a companion therapy for a drug candidate that is currently in human clinical trials with Niemann-Pick Type C patients,” she said. will be enhanced with an interface to allow clinicians to more easily build lessons.” Brooke Beier, assistant director of business development at Purdue Research Foundation Office of Technology Commercialization, said the startups selected for this round of awards established themselves as strong candidates for the funding because they focused on how their work could improve people’s lives. “The EIF board recognized the importance of helping these two companies bridge the gap between research and commercialization and felt the investment will create a value inflection point for them to accomplish their next milestones. The Emerging Innovations Fund is a self-sustaining initiative that brings together ideas, management and money to accelerate the commercialization of early-stage technologies in the Purdue community.